Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Best Of BIO: Policy & Regulatory Updates From BIO 2017

Executive Summary

Antibiotic incentives, vaccine strategies, drug pricing, patent updates and more hot topics from the Biotechnology Innovation Organization's recent annual conference.

You may also be interested in...



LPAD Approval Pathway Is Not Saving Antimicrobial Development

US FDA and CMS explore reimbursement ideas to strengthen business case for antimicrobial development; new approval pathway likely is only needed in special situations.

Gottlieb Floats New Antibiotic Payment Model In LPAD Announcement

US FDA Commissioner outlines licensing fee reimbursement arrangement intended to provide better financial incentives for development.

Aldeyra's Allergy Drug Misses Endpoint But Company Sees Market Gap

Aldeyra is moving ahead with plans for Phase III trials of its novel allergy drug in the face of a missed Phase IIb endpoint. Its ultimate success could rest on what endpoint the FDA will accept.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC143367

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel